ArticleJournal for immunotherapy of cancer2019

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.

Stefanie R Mullins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.